- Idiopathic Gastroparesis
- Diabetic Gastroparesis
- Surgery
- Nervous System Disorders
- Others
Gastroparesis Management Market size was valued at USD 4,348.61 million in 2022 and is poised to grow at a CAGR of 4.6% from 2023 to 2029. Gastroparesis is also called delayed gastric emptying, is a disorder of the stomach that hinders the movement of food from the stomach to the small intestine. Generally, muscles of the GI tract are controlled by the vagus nerve, which contracts to move the food contents throughout the GI tract. Gastroparesis occurs when the vagus nerve is damaged by illness or injury which leads to slower movement of food contents from the stomach to the small intestine. The majority of people with gastroparesis have idiopathic gastroparesis of which the cause is unknown. Diabetes is commonly known as the cause of gastroparesis. Elevated sugar levels in diabetics are believed to cause damage to the vagus nerve and other causes of gastroparesis include gastric surgery, Parkinson's disease, and multiple sclerosis. Gastroparesis is generally found in females than males. The gastroparesis management market report evaluates all-inclusive data that enriches the scope, understanding, and application of this report. Gastroparesis is a condition that primarily affects diabetics with type 1 and type 2 diabetes. The stomach takes an abnormally long time to empty its contents in this condition. Gastroparesis is treated with drugs such as erythromycin, antiemetics, and Reglan. Furthermore, due to the increased prevalence of type 1 and type 2 diabetes, which may increase the risk of gastroparesis, there are 119 completed and continuing clinical trials for gastroparesis medicines. This increases the demand for these drugs and, to some extent, fuels the total market. However, the market may be hampered by adverse effects associated with gastroparesis medications.
Global Gastroparesis Management Market Summary
Study Period
2023-29
Base Year
2022
CAGR
4.6%
Largest Market
North America
Fastest Growing Market
Asia Pacific
Gastroparesis Management Market Dynamics
Rising prevalence of diabetes and gastroparesis, increasing gastroparesis awareness among healthcare professionals expected to propel market for gastroparesis management market over the forecast period. Moreover, rising clinical development candidates for treating gastroparesis is expected to fuel the market revenue for gastroparesis management market. For instance, as of now, there are around six drug candidates in clinical development which act by different mechanisms and route of administration. However, a dearth of specific treatment options, large medical unmet need, and lack of gastroparesis management guidelines expected to hamper the Gastroparesis Management Market over the forecast period.
North-America Got Significant Share of
Gastroparesis Management Market Regional Analysis
North America, Europe, Asia Pacific, Latin America and the Middle East and Africa. North America gastroparesis market is driven by increasing prevalence of disease and potentially 12-16 Mn patients are believed to suffering from gastroparesis in the region. Asia Pacific market expected to grow at significant rate owing to the higher prevalence of diabetes in the region. Asian countries contribute around 60% of the world diabetes population which is expected to drive the market revenue growth. Europe market for gastroparesis management expected to grow at moderate CAGR over forecast period.
Latin America
Europe
Asia Pacific
Middle East
North America
Key Features of the Reports
- The gastroparesis management market report provides granular level information about the market size, regional market share, historic market (2018 to 2022), and forecast (2023 to 2029)
- The report covers in-detail insights about the competitor’s overview, company share analysis, key market developments, and key strategies
- The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market
- The report tracks recent innovations, key developments and startup details that are actively working in the market
- The report provides a plethora of information about market entry strategies, regulatory framework, and reimbursement scenario
- The report analyses the impact of the socio-political environment through PESTLE Analysis and competition through Porter’s Five Force Analysis in addition to recent technology advancements and innovations in the market
Global Gastroparesis Management Market Segmentation
By Cause
By Gastroparesis Type
- Acute Gastroparesis
- Recurrent gastroparesis
By Distribution Channel
- Acute Gastroparesis
- Recurrent gastroparesis
By Intervention Type
- Drugs,
- Surgical Treatment
Frequently Asked Questions
The gastroparesis management market is projected to expand at a CAGR of 16.7% during the forecast period
Abbott Laboratories, Boston Scientific Corporation, C. R. Bard, Inc, Evoke Pharma, Salix Pharmaceuticals, Inc, Janssen Global Services, LLC, Medtronic,
North America is the fastest-growing region for gastroparesis Mmanagement market .
| 1. Executive Summary |
| 2. Global Gastroparesis Management Market Introduction |
| 2.1. Global Gastroparesis Management Market Taxonomy |
| 2.2. Global Gastroparesis Management Market Definitions |
| 2.2.1. By Drug |
| 2.2.2. By Type |
| 2.2.3. By Distribution Channel |
| 2.2.4. By Route of Administration |
| 2.2.5. By Region |
| 3. Global Gastroparesis Management Market Dynamics |
| 3.1. Drivers |
| 3.2. Restraints |
| 3.3. Opportunities/Unmet Needs of the Market |
| 3.4. Trends |
| 3.5. Global Gastroparesis Management Market Dynamic Factors - Impact Analysis |
| 3.6. Impact of COVID 19 on The Market |
| 3.7. Three Forecast Scenarios - Pessimistic, Conservative, and Opportunistic |
| 3.8. Mapping Market Player’s Activities |
| 3.9. Recent Key Developments |
| 3.10. Financial Status of the Market Players |
| 3.11. Recent Acquisitions, Collaborations, and Mergers |
| 4. Global Gastroparesis Management Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 |
| 4.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Million) |
| 4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) |
| 4.3. Market Opportunity Analysis |
| 5. Global Gastroparesis Management Market Forecast, By Drug, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Million) |
| 5.1. Metoclopramide |
| 5.1.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Million) |
| 5.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.1.3. Market Opportunity Analysis |
| 5.2. Erythromycin |
| 5.2.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Million) |
| 5.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.2.3. Market Opportunity Analysis |
| 5.3. Domperidone |
| 5.3.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Million) |
| 5.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.3.3. Market Opportunity Analysis |
| 5.4. Others |
| 5.4.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Million) |
| 5.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.4.3. Market Opportunity Analysis |
| 6. Global Gastroparesis Management Market Forecast, By Type, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Million) |
| 6.1. Diabetic gastroparesis |
| 6.1.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Million) |
| 6.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.1.3. Market Opportunity Analysis |
| 6.2. Idiopathic gastroparesis |
| 6.2.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Million) |
| 6.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.2.3. Market Opportunity Analysis |
| 6.3. Post-surgical gastroparesis |
| 6.3.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Million) |
| 6.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.3.3. Market Opportunity Analysis |
| 6.4. Others |
| 6.4.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Million) |
| 6.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.4.3. Market Opportunity Analysis |
| 7. Market Opportunity Analysis Global Gastroparesis Management Market Forecast, By Distribution Channel, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Million) |
| 7.1. Hospital Pharmacies |
| 7.1.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Million) |
| 7.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.1.3. Market Opportunity Analysis |
| 7.2. Retail Pharmacies |
| 7.2.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Million) |
| 7.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.2.3. Market Opportunity Analysis |
| 7.3. Online Pharmacies |
| 7.3.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Million) |
| 7.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.3.3. Market Opportunity Analysis |
| 8. Market Opportunity Analysis Global Gastroparesis Management Market Forecast, By Route of Administration, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Million) |
| 8.1. Intravenous |
| 8.1.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Million) |
| 8.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 8.1.3. Market Opportunity Analysis |
| 8.2. Nasal |
| 8.2.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Million) |
| 8.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 8.2.3. Market Opportunity Analysis |
| 8.3. Oral |
| 8.3.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Million) |
| 8.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 8.3.3. Market Opportunity Analysis |
| 8.4. Others |
| 8.4.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Million) |
| 8.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 8.4.3. Market Opportunity Analysis |
| 9. Global Gastroparesis Management Market Forecast, By Region, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Million) |
| 9.1. North America |
| 9.1.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Million) |
| 9.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 9.1.3. Market Opportunity Analysis |
| 9.2. Europe |
| 9.2.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Million) |
| 9.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 9.2.3. Market Opportunity Analysis |
| 9.3. Asia-Pacific |
| 9.3.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Million) |
| 9.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 9.3.3. Market Opportunity Analysis |
| 9.4. Latin America |
| 9.4.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Million) |
| 9.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 9.4.3. Market Opportunity Analysis |
| 9.5. Middle East and Africa |
| 9.5.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Million) |
| 9.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 9.5.3. Market Opportunity Analysis |
| 9.6. Global Gastroparesis Management Market - Opportunity Analysis Index, By Drug, Type, Distribution Channel, Route of Administration, and Region, 2023 - 2029 |
| 10. North America Gastroparesis Management Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Million) |
| 10.1. Drug Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (USD Million), Y-o-Y Growth (%) and Market Share (%) |
| 10.1.1. Metoclopramide |
| 10.1.2. Erythromycin |
| 10.1.3. Domperidone |
| 10.1.4. Others |
| 10.2. Type Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (USD Million), Y-o-Y Growth (%) and Market Share (%) |
| 10.2.1. Diabetic gastroparesis |
| 10.2.2. Idiopathic gastroparesis |
| 10.2.3. Post-surgical gastroparesis |
| 10.2.4. Others |
| 10.3. Distribution Channel Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (USD Million), Y-o-Y Growth (%) and Market Share (%) |
| 10.3.1. Hospital Pharmacies |
| 10.3.2. Retail Pharmacies |
| 10.3.3. Online Pharmacies |
| 10.4. Route of Administration Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (USD Million), Y-o-Y Growth (%) and Market Share (%) |
| 10.4.1. Intravenous |
| 10.4.2. Nasal |
| 10.4.3. Oral |
| 10.4.4. Others |
| 10.5. Country Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (USD Million) Y-o-Y Growth (%) and Market Share (%) |
| 10.5.1. U.S. |
| 10.5.2. Canada |
| 10.6. North America Gastroparesis Management Market - Opportunity Analysis Index, By Drug, Type, Distribution Channel, Route of Administration, and Country, 2023 - 2029 |
| 10.7. North America Gastroparesis Management Market Dynamics Trends |
| 11. Europe Gastroparesis Management Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Million) |
| 11.1. Drug Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (USD Million), Y-o-Y Growth (%) and Market Share (%) |
| 11.1.1. Metoclopramide |
| 11.1.2. Erythromycin |
| 11.1.3. Domperidone |
| 11.1.4. Others |
| 11.2. Type Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (USD Million), Y-o-Y Growth (%) and Market Share (%) |
| 11.2.1. Diabetic gastroparesis |
| 11.2.2. Idiopathic gastroparesis |
| 11.2.3. Post-surgical gastroparesis |
| 11.2.4. Others |
| 11.3. Distribution Channel Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (USD Million), Y-o-Y Growth (%) and Market Share (%) |
| 11.3.1. Hospital Pharmacies |
| 11.3.2. Retail Pharmacies |
| 11.3.3. Online Pharmacies |
| 11.4. Route of Administration Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (USD Million), Y-o-Y Growth (%) and Market Share (%) |
| 11.4.1. Intravenous |
| 11.4.2. Nasal |
| 11.4.3. Oral |
| 11.4.4. Others |
| 11.5. Country Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (USD Million) Y-o-Y Growth (%) and Market Share (%) |
| 11.5.1. Germany |
| 11.5.2. UK |
| 11.5.3. France |
| 11.5.4. Italy |
| 11.5.5. Spain |
| 11.5.6. Rest of Europe |
| 11.6. Europe Gastroparesis Management Market - Opportunity Analysis Index, By Drug, Type, Distribution Channel, Route of Administration, and Country, 2023 - 2029 |
| 11.7. Europe Gastroparesis Management Market Dynamics Trends |
| 12. Asia-Pacific Gastroparesis Management Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Million) |
| 12.1. Drug Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (USD Million), Y-o-Y Growth (%) and Market Share (%) |
| 12.1.1. Metoclopramide |
| 12.1.2. Erythromycin |
| 12.1.3. Domperidone |
| 12.1.4. Others |
| 12.2. Type Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (USD Million), Y-o-Y Growth (%) and Market Share (%) |
| 12.2.1. Diabetic gastroparesis |
| 12.2.2. Idiopathic gastroparesis |
| 12.2.3. Post-surgical gastroparesis |
| 12.2.4. Others |
| 12.3. Distribution Channel Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (USD Million), Y-o-Y Growth (%) and Market Share (%) |
| 12.3.1. Hospital Pharmacies |
| 12.3.2. Retail Pharmacies |
| 12.3.3. Online Pharmacies |
| 12.4. Route of Administration Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (USD Million), Y-o-Y Growth (%) and Market Share (%) |
| 12.4.1. Intravenous |
| 12.4.2. Nasal |
| 12.4.3. Oral |
| 12.4.4. Others |
| 12.5. Country Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (USD Million) Y-o-Y Growth (%) and Market Share (%) |
| 12.5.1. Japan |
| 12.5.2. China |
| 12.5.3. India |
| 12.5.4. ASEAN |
| 12.5.5. Rest of Asia-Pacific |
| 12.6. Asia-Pacific Gastroparesis Management Market - Opportunity Analysis Index, By Drug, Type, Distribution Channel, Route of Administration, and Country, 2023 - 2029 |
| 12.7. Asia-Pacific Gastroparesis Management Market Dynamics Trends |
| 13. Latin America Gastroparesis Management Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Million) |
| 13.1. Drug Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (USD Million), Y-o-Y Growth (%) and Market Share (%) |
| 13.1.1. Metoclopramide |
| 13.1.2. Erythromycin |
| 13.1.3. Domperidone |
| 13.1.4. Others |
| 13.2. Type Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (USD Million), Y-o-Y Growth (%) and Market Share (%) |
| 13.2.1. Diabetic gastroparesis |
| 13.2.2. Idiopathic gastroparesis |
| 13.2.3. Post-surgical gastroparesis |
| 13.2.4. Others |
| 13.3. Distribution Channel Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (USD Million), Y-o-Y Growth (%) and Market Share (%) |
| 13.3.1. Hospital Pharmacies |
| 13.3.2. Retail Pharmacies |
| 13.3.3. Online Pharmacies |
| 13.4. Route of Administration Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (USD Million), Y-o-Y Growth (%) and Market Share (%) |
| 13.4.1. Intravenous |
| 13.4.2. Nasal |
| 13.4.3. Oral |
| 13.4.4. Others |
| 13.5. Country Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (USD Million) Y-o-Y Growth (%) and Market Share (%) |
| 13.5.1. Brazil |
| 13.5.2. Argentina |
| 13.5.3. Rest of Latin America |
| 13.6. Latin America Gastroparesis Management Market - Opportunity Analysis Index, By Drug, Type, Distribution Channel, Route of Administration, and Country, 2023 - 2029 |
| 13.7. Latin America Gastroparesis Management Market Dynamics Trends |
| 14. Middle East and Africa Gastroparesis Management Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Million) |
| 14.1. Drug Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (USD Million), Y-o-Y Growth (%) and Market Share (%) |
| 14.1.1. Metoclopramide |
| 14.1.2. Erythromycin |
| 14.1.3. Domperidone |
| 14.1.4. Others |
| 14.2. Type Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (USD Million), Y-o-Y Growth (%) and Market Share (%) |
| 14.2.1. Diabetic gastroparesis |
| 14.2.2. Idiopathic gastroparesis |
| 14.2.3. Post-surgical gastroparesis |
| 14.2.4. Others |
| 14.3. Distribution Channel Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (USD Million), Y-o-Y Growth (%) and Market Share (%) |
| 14.3.1. Hospital Pharmacies |
| 14.3.2. Retail Pharmacies |
| 14.3.3. Online Pharmacies |
| 14.4. Route of Administration Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (USD Million), Y-o-Y Growth (%) and Market Share (%) |
| 14.4.1. Intravenous |
| 14.4.2. Nasal |
| 14.4.3. Oral |
| 14.4.4. Others |
| 14.5. Country Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (USD Million) Y-o-Y Growth (%) and Market Share (%) |
| 14.5.1. Saudi Arabia |
| 14.5.2. GCC Countries |
| 14.5.3. South Africa |
| 14.5.4. Rest of MEA |
| 14.6. MEA Gastroparesis Management Market - Opportunity Analysis Index, By Drug, Type, Distribution Channel, Route of Administration, and Country, 2023 - 2029 |
| 14.7. MEA Gastroparesis Management Market Dynamics Trends |
| 15. Competition Landscape |
| 15.1. Strategic Dashboard of Top Market Players |
| 15.2. Company Profiles (Introduction, Financial Analysis, Drug Offerings, Key Developments, Strategies, and SWOT Analysis) |
| 15.2.1. Evoke Pharma |
| 15.2.2. Neurogastrx |
| 15.2.3. Takeda Pharmaceutical |
| 15.2.4. Pfizer |
| 15.2.5. Atlantic Healthcare |
| 15.2.6. Salix Pharmaceuticals, Inc. |
| 15.2.7. ANI Pharmaceuticals |
| 15.2.8. Processa Pharmaceuticals, Inc. |
| 15.2.9. Vanda Pharmaceuticals Inc |
| 15.2.10. CinDome Pharma, Inc.Oracle Corporation |
| 16. Research Methodology |
| 17. Key Assumptions and Acronyms |
- Evoke Pharma
- Neurogastrx
- Takeda Pharmaceutical
- Pfizer
- Atlantic Healthcare
- Salix Pharmaceuticals, Inc.
- ANI Pharmaceuticals
- Processa Pharmaceuticals, Inc.
- Vanda Pharmaceuticals Inc
- CinDome Pharma, Inc.Oracle Corporation